News

Filter by:

Showing 12 of 550 Results

September 22, 2023 General News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 19, 2023 General News

Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

September 18, 2023 Company Statement

Acadia Pharmaceuticals Announces Label Update for NUPLAZID® (pimavanserin)

August 30, 2023 General News

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

August 14, 2023 General News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 2, 2023 Earnings News

Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview

August 1, 2023 General News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 24, 2023 General News

Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer

July 19, 2023 General News

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023

July 13, 2023 General News

Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome

June 26, 2023 General News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 13, 2023 General News

Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome

Load More Results